Results 21 to 30 of about 82,604 (202)

Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E‐mutated lung adenocarcinoma

Respirology Case Reports, 2021
V‐raf murine sarcoma viral oncogene homologue B1 (BRAF) is a proto‐oncogene that regulates cell proliferation and survival. BRAF V600E‐mutated lung cancer has aggressive characteristics and is resistant to chemotherapies.
Takayo Ota, Aya Okabayashi, Masahiro Fukuoka   +2 more
doaj   +1 more source

Biological challenges of BRAF inhibitor therapy [PDF]

Molecular Oncology, 2011
Activating mutations in BRAF, a constituent of the map kinase pathway, were first discovered as being most prevalent in melanoma in 2002. Only recently have potent and selective, orally available inhibitors of BRAF emerged for clinical testing and demonstrated clear evidence of tumor regression in the majority of patients whose tumors harbor a BRAF ...
Igor, Puzanov, Patrick, Burnett, Keith T, Flaherty   +2 more
openaire   +2 more sources

PIK3CA mutations in advanced cancers: characteristics and outcomes. [PDF]

, 2012
PIK3CA mutations are frequently diagnosed in diverse cancers and may predict response to PI3K/AKT/mTOR inhibitors. It remains unclear whether they are associated with other characteristics.
Falchook, Gerald S, Fu, Siqing, Garrido-Laguna, Ignacio, Hong, David S, Janku, Filip, Kurzrock, Razelle, Lee, Jack J, Luthra, Rajyalakshmi, Moulder, Stacy L, Naing, Aung, Piha-Paul, Sarina A, Stepanek, Vanda M, Tsimberidou, Apostolia M, Wheler, Jennifer J   +13 more
core   +4 more sources

BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions. [PDF]

Cancers (Basel), 2020
The BRAF inhibitors vemurafenib, dabrafenib and encorafenib are used in the treatment of patients with BRAF-mutant melanoma. They selectively target BRAF kinase and thus interfere with the mitogen-activated protein kinase (MAPK) signalling pathway that regulates the proliferation and survival of melanoma cells. In addition to their molecularly targeted
Proietti I, Skroza N, Michelini S, Mambrin A, Balduzzi V, Bernardini N, Marchesiello A, Tolino E, Volpe S, Maddalena P, Di Fraia M, Mangino G, Romeo G, Potenza C.   +13 more
europepmc   +4 more sources

Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature

Dermatology Research and Practice, 2016
The incidence of melanoma has recently been increasing. BRAF mutations have been found in 40–60% of melanomas. The increased activity of BRAF V600E leads to the activation of downstream signaling through the mitogen-activated protein kinase (MAPK ...
Bilgen Gençler, Müzeyyen Gönül
doaj   +1 more source

Agents to treat BRAF-mutant lung cancer

Drugs in Context, 2019
BRAF mutations are seen in up to 3.5–4% of the non-small cell lung cancer (NSCLC) patients. BRAF V600E mutations account for 50% of these cases, and the remaining BRAF mutations are non-V600E. The biologic behavior of BRAF-mutated lung tumors tends to be
Jean G Bustamante Alvarez, Gregory A Otterson   +1 more
doaj   +1 more source

BRAF L485–P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review

Frontiers in Pharmacology, 2023
Background: The combination therapy of BRAF inhibitors (BRAFis) and MEK inhibitors (MEKis) has been approved as a first-line treatment for metastatic melanoma with BRAF V600 mutants. Recently, BRAF mutations have been divided into three subtypes based on
Simeng Zhang, Simeng Zhang, Simeng Zhang, Zichang Yang, Zichang Yang, Zichang Yang, Yu Cheng, Yu Cheng, Yu Cheng, Xiaoyu Guo, Xiaoyu Guo, Xiaoyu Guo, Chang Liu, Chang Liu, Chang Liu, Shuo Wang, Shuo Wang, Shuo Wang, Lingyun Zhang, Lingyun Zhang, Lingyun Zhang   +20 more
doaj   +1 more source

MEK inhibitors for the treatment of non-small cell lung cancer

Journal of Hematology & Oncology, 2021
BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway. Concomitant mutations in both KRAS and BRAF genes have been identified in non-small cell lung cancer (NSCLC). They lead to the proliferation, differentiation, and apoptosis of
Jing Han, Yang Liu, Sen Yang, Xuan Wu, Hongle Li, Qiming Wang   +5 more
doaj   +1 more source

Melanoma subpopulations that rapidly escape MAPK pathway inhibition incur DNA damage and rely on stress signalling

Nature Communications, 2021
BRAF inhibitors are used to treat late-stage melanoma patients harbouring BRAF mutations. Here the authors track the responses of single melanoma cells to BRAF inhibitors and show that a subset of cells rapidly escapes drug via non-genetic mechanisms and
Chen Yang, Chengzhe Tian, Timothy E. Hoffman, Nicole K. Jacobsen, Sabrina L. Spencer   +4 more
doaj   +1 more source

Computational evaluation of potent 2-(1H-imidazol-2-yl) pyridine derivatives as potential V600E-BRAF inhibitors

Egyptian Journal of Medical Human Genetics, 2020
Background V600E-BRAF is a major protein target involved in various types of human cancers. However, the acquired resistance of the V600E-BRAF kinase to the vemurafenib and the side effects of other identified drugs initiate the search for efficient ...
Abdullahi Bello Umar, Adamu Uzairu, Gideon Adamu Shallangwa, Sani Uba   +3 more
doaj   +1 more source